/HLUN-B.CO

HLUN-B.CO Stock - H. Lundbeck A/S

Q: What is the analyst price target for HLUN-B.CO?

Analyst price target information is not currently available for HLUN-B.CO.

Q: What is HLUN-B.CO's market cap?

Market capitalization information is not currently available for HLUN-B.CO.

Healthcare|Drug Manufacturers - Specialty & Generic|CPH

$43.00+0.00%

+$0.00 (+0.00%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $47.30

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for HLUN-B.CO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.38

52W High$47.78

52W Low$27.20

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$22.00B	$19.91B	$18.25B	$16.30B	$17.67B
Gross Profit	$17.77B	$15.43B	$14.29B	$12.65B	$13.50B
Gross Margin	80.8%	77.5%	78.3%	77.6%	76.4%
Operating Income	$3.27B	$3.19B	$2.85B	$2.01B	$1.99B
Net Income	$3.14B	$2.29B	$1.92B	$1.32B	$1.58B
Net Margin	14.3%	11.5%	10.5%	8.1%	8.9%
EPS	$3.17	$2.31	$1.93	$1.66	$7.96

Company Overview

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Visit Website

Earnings History & Surprises

HLUN-B.CO

Beat Rate

79%

Last 19 quarters

Avg Surprise

+14.3%

EPS vs Estimate

Beats / Misses

15/3

1 met exactly

Latest EPS

$1.11

Q4 2025

EPS Surprise History

Q1 24

-24.0%

$0.57vs$0.75

Q2 24

+7.0%

$1.38vs$1.29

Q3 24

+5.9%

$1.26vs$1.19

Q4 24

-5.8%

$1.30vs$1.38

Q1 25

+63.9%

$1.36vs$0.83

Q2 25

+17.7%

$1.53vs$1.30

Q3 25

-27.1%

$0.97vs$1.33

Q4 25

0.0%

$1.11vs$1.11

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 4, 2026	$1.16	—	—	—
Q4 2025	Nov 11, 2025	$1.11	$1.11	0.0%	= MET
Q3 2025	Aug 12, 2025	$1.33	$0.97	-27.1%	✗ MISS
Q2 2025	May 14, 2025	$1.30	$1.53	+17.7%	✓ BEAT
Q1 2025	Feb 5, 2025	$0.83	$1.36	+63.9%	✓ BEAT
Q4 2024	Nov 13, 2024	$1.38	$1.30	-5.8%	✗ MISS
Q3 2024	Aug 20, 2024	$1.19	$1.26	+5.9%	✓ BEAT
Q2 2024	May 15, 2024	$1.29	$1.38	+7.0%	✓ BEAT
Q1 2024	Feb 7, 2024	$0.75	$0.57	-24.0%	✗ MISS
Q4 2023	Nov 8, 2023	$1.07	$1.17	+9.3%	✓ BEAT
Q3 2023	Aug 16, 2023	$0.86	$1.11	+29.1%	✓ BEAT
Q2 2023	May 10, 2023	$1.01	$1.36	+34.7%	✓ BEAT
Q1 2023	Feb 7, 2023	$0.46	$0.61	+32.6%	✓ BEAT
Q4 2022	Nov 9, 2022	$0.72	$0.96	+33.3%	✓ BEAT
Q3 2022	Aug 17, 2022	$0.70	$0.71	+1.4%	✓ BEAT
Q2 2022	May 11, 2022	$3.38	$4.67	+38.2%	✓ BEAT
Q1 2022	Feb 9, 2022	$1.89	$2.09	+10.6%	✓ BEAT
Q4 2021	Nov 10, 2021	$2.06	$2.78	+35.0%	✓ BEAT
Q3 2021	Aug 18, 2021	$1.83	$1.90	+3.8%	✓ BEAT
Q2 2021	May 11, 2021	$2.97	$3.13	+5.4%	✓ BEAT

Frequently Asked Questions about HLUN-B.CO

What is HLUN-B.CO's current stock price?

H. Lundbeck A/S (HLUN-B.CO) is currently trading at $43.00 per share. The stock has moved +0.00% today.

What is the analyst price target for HLUN-B.CO?

No analyst price targets are currently available for this stock.

What sector is H. Lundbeck A/S in?

H. Lundbeck A/S operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the CPH exchange.

What is HLUN-B.CO's market cap?

H. Lundbeck A/S has a market capitalization of $34.07 billion, making it a large-cap company.

Does HLUN-B.CO pay dividends?

No, H. Lundbeck A/S does not currently pay a dividend to shareholders.